CJC-1295 with DAC vs without DAC

TL;DR

• CJC-1295 without DAC is also known as MOD GRF 1-29. Short half-life (~30 minutes). Injected 2–3x daily. Produces short, sharp GH pulses.
• CJC-1295 with DAC has a Drug Affinity Complex attached. The DAC binds to albumin and extends half-life to roughly 6–8 days. Injected once or twice weekly. Produces sustained GH elevation rather than pulses.
• The shorthand: without DAC = pulses (more natural). With DAC = sustained release (more convenient).

If you only remember one thing: more convenient isn't more biologically correct. Natural GH is pulsatile for a reason.

The headline difference, in one sentence

Without DAC mimics the way the body releases GH — in sharp pulses. With DAC keeps GH elevated for days at a time, which is convenient but unlike anything that happens naturally.

What's the difference, technically

Both versions are based on the same modified GHRH 1-29 fragment. The only difference is whether a "Drug Affinity Complex" (DAC) — a maleimide group that covalently binds to a cysteine on circulating albumin — is attached.

Pick CJC-1295 without DAC (MOD GRF 1-29) if...

• You want physiologically realistic GH pulses that match the body's own rhythm.
• You're researching endogenous-style GH biology — pulsatile signaling matters for many downstream effects.
• You want a cleaner side-effect profile with less flushing or water retention.
• You're building a classic GHRH + GHRP stack (pairs naturally with Ipamorelin) and want both to pulse together.
• You don't mind multiple injections per day.

Pick CJC-1295 with DAC if...

• Convenience is the deciding factor — weekly dosing vs 2–3x daily.
• The research target is sustained IGF-1 elevation rather than physiological GH pulses.
• You're studying scenarios where GH bleed-over is acceptable or specifically desired.
• You're willing to accept a higher rate of flushing, lethargy, or water retention as part of the protocol.

Why "more convenient" isn't always "better"

Natural GH is released in pulses for a reason. Pulsatile signaling drives different gene expression than sustained signaling. A few things to weigh:

• Sustained GH ("GH bleed") may desensitize GH receptors over time in ways that pulsatile dosing doesn't.
• Pulsatile GH supports night-time GH peaks (the largest natural pulses occur during deep sleep). DAC versions flatten this rhythm.
• The original clinical interest in CJC-1295 with DAC focused on populations where sustained GH was an acceptable tradeoff for once-weekly dosing convenience. Most of the experienced research community has moved toward MOD GRF 1-29 for protocol research.

Honest tradeoffs

• Naming confusion: "MOD GRF 1-29" and "CJC-1295 (no DAC)" are the same molecule. Suppliers use both names interchangeably. If a vendor lists both, that's a red flag — they're not distinct products.
• DAC version side effects are commonly reported as more pronounced: flushing, fatigue, water retention, occasional headaches. These are dose-dependent.
• The "weekly injection" benefit mostly matters if injection frequency is your primary barrier. If you're already doing daily injections of Ipamorelin or other peptides, adding a third daily injection of MOD GRF is marginal additional friction.
• DAC-bound peptide cleared via albumin turnover — this is a slow, steady process that doesn't allow the natural pulse architecture.

Quick decision shortcut

Where to read more

• Full breakdown of CJC-1295 (no DAC).
• Full breakdown of CJC-1295 with DAC.
• The naming explainer: MOD GRF 1-29 and why it's called that.
• Stack pairings: CJC-1295 + Ipamorelin Stack, CJC-1295 DAC + Ipamorelin Stack.
• Background: Sermorelin vs Ipamorelin for the GHRH-vs-GHRP basics.

Important context

Both versions of CJC-1295 are research peptides without FDA approval for any indication. Pre-clinical and limited human trial data exist. Nothing on this page is medical advice.